Search Legislation

Advanced Search

National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004

Status:

Point in time view as at 20/04/2011.

Changes to legislation:

There are currently no known outstanding effects for the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004, SCHEDULE 2. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Regulation 3

SCHEDULE 2E+WDRUGS, MEDICINES AND OTHER SUBSTANCES THAT MAY BE ORDERED ONLY IN CERTAIN CIRCUMSTANCES

Column 1Column 2Column 3
DrugsPatientPurpose
ClobazamAny patientTreatment of epilepsy
Cyanocobalamin TabletsA patient who is a vegan or who has a proven vitamin B12 deficiency of dietary originTreatment or prevention of vitamin B12 deficiency
Locabiotal AerosolAny patientTreatment of infections and inflammation of the oropharynx
Niferex Elixir 30ml Paediatric Dropper BottleInfants born prematurelyProphylaxis and treatment of iron deficiency
Nizoral CreamAny patientTreatment of seborrhoeic dermatitis and pityriasis versicolor
[F1Oseltamivir (Tamiflu)]

[F1(1) [F2A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, [F3or who is aged under 65 years and is at risk of developing medical complications from influenza,] where—

(a)the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;]

(b)the patient has an influenza-like illness; and

(c)the patient can start therapy within 48 hours of the onset of symptoms.]

[F4(1A) Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or are part of a Primary Care Trust’s antivirals distribution service.]

[F1Treatment of influenza]

[F1(2) [F5A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—

(a)the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;]

(b)the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;

(c)the patient is not effectively protected by vaccination against influenza because—

(i)he has not been vaccinated because vaccination is contraindicated;

(ii)he has not been vaccinated since the previous influenza season;

(iii)he has been vaccinated but it has yet to take effect; or

(iv)he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;

(d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and

(e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.]

[F6(2A) Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or are part of a Primary Care Trust’s antivirals distribution service.]

[F1Prophylaxis of influenza]
[F1Zanamivir (Relenza)]

[F7(1)] [F8A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, [F9or who is aged under 65 years and is at risk of developing medical complications from influenza,] where—

(a)the Department of Health has notified general medical practitioners that the influenza virus is circulating in the community;]

(b)the patient has an influenza-like illness; and

[F10(c) in the case of a patient—

(i)who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; and

(ii)who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.]

[F1Treatment of influenza ]

[F11(2) Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Secretary of State or are part of a Primary Care Trust’s antivirals distribution service.]

[F12Prophylaxis or treatment of influenza.]

The following drugs for the treatment of erectile dysfunction—

  • Alprostadil (Caverject), (MUSE), (Viridal)

  • Apomorphine Hydrochloride (Uprima)

  • Moxisylyte Hydrochloride (Erecnos)

  • Sildenafil (Viagra)

  • Tadalafil (Cialis)

  • Thymoxamine Hydrochloride (Erecnos)

  • Vardenafil (Levitra)

(a)a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland ) Act 1978 M1 or the Health and Personal Social Services (Northern Ireland) Order 1972 M2for this condition with any of the following drugs—

  • Alprostadil (Caverject), (MUSE), (Viridal)

  • Apomorphine Hydrochloride (Uprima)

  • Moxisylyte Hydrochloride (Erecnos)

  • Sildenafil (Viagra)

  • Tadalafil (Cialis)

  • Thymoxamine

  • Hydrochloride (Erecnos); or

(b)a man who is not a national of an EEA State but who is the member of the family of such a national who has anenforceable Community right to be treated no less favourably than the national in the provision of medical treatmentand has erectile dysfunction and was being treated for that condition on 14th September 1998 with any of the drugs listed in sub-paragraph (a); or

(c)a man who is a national of an EEA State who is entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 M2as extended by the EEA Agreement or by virtue of any other enforceable Community right who has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for this condition with any of the drugs listed in sub-paragraph (a); or

(d)a man who is suffering from any of the following—

  • diabetes

  • multiple sclerosis

  • parkinson’s disease

  • poliomyelitis

  • prostate cancer

  • severe pelvic injury

  • single gene neurological disease

  • spina bifida

  • spinal cord injury; or

(e)a man who is receiving treatment for renal failure by dialysis; or

(f)a man who has had the following surgery—

  • prostatectomy

  • radical pelvic surgery

  • renal failure treated by transplant

Treatment of erectile dysfunction

Textual Amendments

Marginal Citations

In this Schedule—

F13...

Textual Amendments

[F14“at clinical risk” means in relation to a patient, a patient who—

(a)has chronic respiratory disease;

(b)has asthma that requires continuous or repeated use of inhaled or systemic steroids or with previous exacerbations requiring hospital admission;

(c)has chronic heart disease;

(d)has chronic renal failure;

(e)has chronic liver disease;

(f)has chronic neurological disease;

(g)has diabetes; or

(h)is immunosuppressed;]

Textual Amendments

F13...

Textual Amendments

“EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992 M3 as adjusted by the Protocol signed at Brussels on 17th March 1993 M4 and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994 M5; and

Marginal Citations

M3Cm. 2073 and O.J. No. L1, 3.1.1994, p.3.

M4Cm. 2183 and O.J. No. L1, 3.1.1994, p.572.

M5O.J. No. L160, 28.6.1996, p.1.

“EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland.

[F14“general medical practitioner” has the same meaning as in the National Health Services (General Medical Services Contracts) Regulations 2004;]

Textual Amendments

[F15“patient” has the same meaning as in the National Health Services (General Medical Services Contracts) Regulations 2004;]

Textual Amendments

[F15“residential care establishment” means a place where persons reside on a long term basis in order to receive continuing care.]

Textual Amendments

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources

The data on this page is available in the alternative data formats listed: